Affymax fires 75% of workers, mulls bankruptcy
This article was originally published in Scrip
Executive Summary
Any hope that Affymax can recover from the recall of its Omontys anemia therapy for kidney patients disappeared with the company’s announcement that it's firing 75% of its workforce and is considering a bankruptcy filing.